Weekly Investment Analysts’ Ratings Updates for Oruka Therapeutics (ORKA)

Several analysts have recently updated their ratings and price targets for Oruka Therapeutics (NASDAQ: ORKA):

• 4/15/2026 – Oruka Therapeutics had its price target raised by Wedbush from $45.00 to $85.00. They now have an “outperform” rating on the stock.
• 4/13/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $125.00 price target on the stock.
• 4/13/2026 – Oruka Therapeutics had its price target raised by HC Wainwright from $40.00 to $70.00. They now have a “buy” rating on the stock.
• 4/13/2026 – Oruka Therapeutics had its price target raised by BTIG Research from $73.00 to $78.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Oruka Therapeutics had its price target raised by Barclays PLC from $50.00 to $78.00. They now have an “overweight” rating on the stock.
• 4/6/2026 – Oruka Therapeutics had its price target raised by UBS Group AG from $50.00 to $75.00. They now have a “buy” rating on the stock.
• 3/16/2026 – Oruka Therapeutics had its price target raised by Leerink Partners from $58.00 to $86.00. They now have an “outperform” rating on the stock.
• 3/16/2026 – Oruka Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/13/2026 – Oruka Therapeutics had its price target raised by Barclays PLC from $48.00 to $50.00. They now have an “overweight” rating on the stock.
• 3/13/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $73.00 price target on the stock.
• 3/13/2026 – Oruka Therapeutics had its price target raised by Stifel Nicolaus from $47.00 to $72.00. They now have a “buy” rating on the stock.
• 3/13/2026 – Oruka Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $45.00 price target on the stock.
• 3/13/2026 – Oruka Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $60.00 price target on the stock.
• 3/8/2026 – Oruka Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/28/2026 – Oruka Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Transactions at Oruka Therapeutics

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares in the company, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares in the company, valued at $1,365,453.07. This represents a 18.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,765 shares of company stock valued at $1,089,745 in the last ninety days. Insiders own 24.69% of the company’s stock.

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.